Sugi Predict

Sugi Predict / Compounds / SCHEMBL4577378

SCHEMBL4577378

SCHEMBL4577378

Nc1ccc2c(c1)CS(=O)(=O)N2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.41
▸ GAA P10253 4/20 0.41
▸ KDM4E B2RXH2 4/20 0.41
▸ CASP1 P29466 2/20 0.41
▸ CASP7 P55210 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ RECQL P46063 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ CA9 Q16790 3/20 0.38
▸ CA12 O43570 2/20 0.38
▸ ABCC8 Q09428 1/20 0.37
▸ KCNJ11 Q14654 1/20 0.37
▸ CCNC P24863 2/20 0.36
▸ CDK8 P49336 2/20 0.36
▸ LMNA P02545 3/20 0.35
▸ MEN1 O00255 3/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ RAB9A P51151 2/20 0.33
▸ CA1 P00915 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3600994 0.83 CA9 (0.39) MAPTGAAKDM4ECASP1CASP7
SCHEMBL36942249 0.78 CA2 (0.42) CA9CA12CCNCCDK8CA1
SCHEMBL7904180 0.78 CA1 (0.42) MAPTGAAKDM4EHSD17B10CA9
SCHEMBL21377067 0.78 TDP2 (0.36) CCNCCDK8CA1CA2GRIA1
SCHEMBL15661473 0.78 CA2 (0.42) CA9CA12CCNCCDK8CA1
SCHEMBL8968538 0.77 KDM4E (0.39) MAPTGAAKDM4ECASP1CASP7
Hydrochloric Acid SCHEMBL8968458 0.76 KDM4E (0.38) MAPTGAAKDM4ECASP1CASP7
SCHEMBL7903543 0.74 PARP1 (0.36) MAPTGAAKDM4EL3MBTL1CCNC
SCHEMBL20109740 0.74 CCNC (0.36) MAPTGAAHSD17B10L3MBTL1RECQL
SCHEMBL22326600 0.74 TDP2 (0.41) MEN1KMT2ACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117486865-A Pyrimidine derivatives as kinase inhibitors 艾森医药公司 2024-02-02 — — CN disclosed
CN-112592334-B Pyrimidine derivatives as kinase inhibitors 艾森医药公司 2023-10-27 — — CN disclosed
CN-112592334-A Pyrimidine derivatives as kinase inhibitors 艾森生物科学公司 2021-04-02 — — CN disclosed
US-10562918-B2 Heterocyclic compounds and uses thereof ACEA Therapeutics, Inc. (US) 2020-02-18 — — US disclosed
US-10562918-B2 Heterocyclic compounds and uses thereof ACEA Therapeutics, Inc. (US) 2020-02-18 — — US disclosed
EP-3019496-B1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS ACEA THERAPEUTICS INC (US) 2019-09-11 — — EP disclosed
EP-3019496-B1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS ACEA THERAPEUTICS INC (US) 2019-09-11 — — EP disclosed
US-20180251475-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF ACEA BIOSCIENCES INC. 2018-09-06 — — US disclosed
US-9920074-B2 Heterocyclic compounds and uses thereof ACEA BIOSCIENCES INC. (US) 2018-03-20 — — US disclosed
US-9920074-B2 Heterocyclic compounds and uses thereof ACEA BIOSCIENCES INC. (US) 2018-03-20 — — US disclosed
US-7453000-B2 Substituted oxazolobenzoisothiazole dioxide derivatives method for production and use thereof SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-11-18 — — US disclosed
US-7435744-B2 Piperidine derivatives as NMDA receptor antagonists GEDEON RICHTER VEGYESZETI GYAR RT (HU) 2008-10-14 — — US disclosed
EP-1409477-B1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON NYRT (HU) 2008-09-17 — — EP disclosed
CN-100413860-C piperidine derivatives as NMDA receptor antagonists HUNGARY GIREL GYOGYSZERGYAR (HU) 2008-08-27 — — CN disclosed
US-20070149511-A1 SUBSTITUTED OXAZOLOBENZOISOTHIAZOLE DIOXIDE DERIVATIVES METHOD FOR PRODUCTION AND USE THEREOF SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-28 — — US disclosed
US-20070149511-A1 SUBSTITUTED OXAZOLOBENZOISOTHIAZOLE DIOXIDE DERIVATIVES METHOD FOR PRODUCTION AND USE THEREOF SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-28 — — US disclosed
CN-1556805-A piperidine derivatives as NMDA receptor antagonists ������ҩ�����޹�˾ 2004-12-22 — — CN disclosed
US-20040157886-A1 Piperdine derivatives as NMDA receptor antagonists UCB Biopharma SRL (BE) 2004-08-12 — — US disclosed
EP-1409477-A1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 2004-04-21 — — EP disclosed
WO-2003010159-A1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS Richter Gedeon Vegyészeti Gyár Rt. (HU) 2003-02-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149511-A1 SUBSTITUTED OXAZOLOBENZOISOTHIAZOLE DIOXIDE DERIVATIVES METHOD FOR PRODUCTION AND USE THEREOF SLC5A2, SLC5A1, NOX4 MAPT 3441/4885GAA 777/4885KDM4E 1853/4885
US-10562918-B2 Heterocyclic compounds and uses thereof BMX, BLK, BTK MAPT 2803/4885GAA 2699/4885KDM4E 2158/4885
US-20040157886-A1 Piperdine derivatives as NMDA receptor antagonists GRIN1, GRIN2D, GRIN2C MAPT 3836/4885GAA 4828/4885KDM4E 1161/4885
US-20180251475-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF BMX, BLK, BTK MAPT 2803/4885GAA 2699/4885KDM4E 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.